KAYTUS
23.5.2024 09:40:31 CEST | Business Wire | Press release
KAYTUS, a leading IT infrastructure provider, launched at ISC High Performance 2024 the K22V2, a multi-node server with exceptional compute density and energy efficiency. The K22V2 integrates two independent hot-swap single-socket compute nodes in a 2U form factor. Each node supports either a 4th Gen AMD EPYC™ 9004 series processor with 12 DDR5 RDIMMs (4800MHz) or a 5th Gen Intel® Xeon® processor with eight DDR5 RDIMMs (5600MHz), offering flexible storage and I/O configurations. Each node also supports 6 SATA/NVMe SSDs or 8 E1.S SSDs, along with 4 PCIe 5.0 slots and one OCP NIC 3.0. This makes it an optimal choice for compute-intensive applications, suitable for customers seeking both high compute density and cooling efficiency.
Advanced 1U Computing Density Enhanced by 2U Cooling and O&M Efficiency
Focused on energy efficiency, K22V2 is fitted to accommodate two single-socket nodes within a 2U space, in a horizontal layout. Each node functions as an autonomous server system, enabling independent hot maintenance with plug-and-play support to minimize disruption, thus significantly enhancing O&M efficiency. This design is advantageous for opting for 2U high efficiency heatsinks. A 2U heatsink, due to its effective utilization of vertical space, features a length merely one-fifth that of a 1U heatsink, facilitating a more efficient server layout. Furthermore, the air flow resistance of a 1U heatsink is four times that of a 2U counterpart at the same air volume (50 CFM), necessitating fans with higher power.
According to testing data, the cooling efficiency of the server in a 2U space is superior when two single-socket nodes are horizontally arranged in parallel compared to when two 1U single-socket nodes are vertically stacked. The K22V2 demonstrates 40% better cooling efficiency compared to two standard 1U rack servers under the same computing conditions, while also reducing power consumption by up to 8%.
New pioneering architecture delivers better cost performance efficiency
The K22V2 server features a streamlined modular design where two nodes share the chassis, backplane, fan, and PSU, providing significant L6 cost advantages compared to products with two independent nodes. This pioneering architecture is optimized for high-performance single-socket processors and addresses the issue of high migration costs associated with a single server failure impacting multiple tasks. Consequently, the K22V2 is versatile, supporting a wide range of typical applications from computing to big data, and is ideal for scenarios requiring demanding computing density and cooling efficiency. Additionally, it offers users more convenient O&M.
System Overview |
KAYTUS K22V2 Multi-node server (Side by side) |
Normal 2x 1U servers (Stack up) |
System Configuration |
||
System depth |
880 mm |
850 mm |
CPU Heatsink |
2U EVAC |
1U EVAC |
Fan |
6056*6 |
4056*8 |
CPU Power (EGS) |
300W |
300W |
CPU Core Count |
104 |
208 |
Thermal Evaluation Result |
||
Fan Duty |
50% |
70% |
Total Fan Power |
83.6W |
268.8W |
Fan Power/Per CPU |
41.8W |
67.2W |
Note |
All thermal evaluations are based on conditions of a 35°C ambient temperature, sea level, and a normally operating fan. |
|
About KAYTUS
KAYTUS is a leading provider of IT infrastructure solutions, delivering a diverse range of cutting-edge, open, and eco-friendly products for cloud, AI, edge computing, and other emerging applications. With a customer-centric approach, KAYTUS is agile and responsive to user needs through its adaptable business model. Discover more at KAYTUS.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240523837473/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 202619.2.2026 08:50:00 CET | Press release
Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the selection of an abstract for a poster presentation at the American Association for Cancer Research Immuno-Oncology (AACRIO) annual conference (February 18-21, 2026), in Los Angeles. The poster showcases new preclinical data and early clinical insights from the company's lead candidate, STC-1010, supporting it as a promising therapeutic option for MSS, immune-cold colorectal cancer (CRC)—a major unmet clinical need. In a syngeneic CT26 model, murine STC-1010 significantly inhibits tumor growth and extends survival by 40%. New mechanistic datas reveal expansion of CD4⁺ and CD8⁺ T cells in draining lymph nodes alongside a significant humoral response compared to control, demonstrating coordinated cellular and humoral immune activation in vivo. Other findings show that dendritic cells efficiently capture STC-1010, leading to their activation as demonstrated by transcripto
ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer19.2.2026 08:30:00 CET | Press release
Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-DM1 If approved, Daiichi Sankyo and AstraZeneca’s ENHERTU has the potential to become a new standard of care in this early breast cancer setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committ
NHOA Energy Advances Delivery of the 51 MWh Broni Battery for Neoen in Italy19.2.2026 08:00:00 CET | Press release
The project confirms NHOA Energy’s long-term commitment to the Italian market NHOA Energy, global provider of utility-scale energy storage systems, is advancing the construction of the Broni Battery, a 10 MW/51 MWh project located in Broni (Pavia), Italy, executed for Neoen, one of the world’s leading independent producers of renewable energy. Civil works at the site are currently underway and advancing on schedule, with commissioning activities planned to start in late spring 2026. Once operational, the Broni Battery will provide essential flexibility services to the Italian electricity system, supporting grid stability and reliability as renewable energy penetration continues to increase. The project represents Neoen’s first battery storage asset in Italy and marks a strategic step in the company’s expansion, as it continues to grow its battery storage portfolio in key markets worldwide to support power system flexibility. The Broni Battery further strengthens NHOA Energy’s long-term
Compass Pathways Announces Pricing of $150 Million Public Offering19.2.2026 02:18:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999 per pre-funded warrant. In addition, Compass Pathways has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 ADSs at the public offering price, less the underwriting discounts and commissions. All of the securities are to be sold by Compass Pathways. The offering is expected to close on or about February 20, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Compass Pathways from the offering, before deducting underwriting discounts and commissions and other est
Andersen Consulting udvider sine kompetencer inden for ledelsesrekruttering med Lansdowne Executive Search18.2.2026 17:08:00 CET | Pressemeddelelse
Andersen Consulting styrker sin humancapital-praksis gennem en samarbejdsaftale med Lansdowne Executive Search, der er en Dublin-baseret virksomhed med speciale i lederrekruttering, midlertidige ledelser og bestyrelsesudnævnelser. Lansdowne Executive Search er en irisk-ejet virksomhed, der blev grundlagt i 2015, og som tilbyder C-level-ledelsesekruttering, deltidsledere og bestyrelsesplaceringer. Som en partnerdrevet boutique-virksomhed er Lansdowne kendt for, at seniorledelsen er tæt involveret i alle kundeprojekter. Virksomheden hjælper kunder med at navigere i komplekse ledelsesovergange og vækststrategier på tværs af en bred vifte af sektorer, herunder finans, byggeindustrien, nonprofit, landbrug, videregående uddannelse, den offentlige sektor samt teknologi, medier og telekommunikation. "God ledelse er afhænger af situationen, og det kræver forståelse af langt mere end blot et CV," sagde Tom Keane, der er partner hos Lansdowne Executive Search. "Samarbejdet med Andersen Consulting
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom